The United Kingdom faces growing calls to strengthen its domestic vaccine manufacturing capabilities as part of a broader strategy to enhance national security against future biological threats. Professor Jonathan Van-Tam, former deputy chief medical officer for England, has highlighted the importance of treating vaccine production with the same priority as energy, food, and defense security.
Van-Tam’s remarks follow a recent report from the Tony Blair Institute for Global Change, which warns that the UK remains vulnerable to pandemics and other biological risks over the next quarter-century. The report estimates the cumulative probability of another pandemic occurring within 25 years at between 47% and 57%, citing annual risks around 2.5% to 3.3%. It identifies a flu pandemic as the most likely scenario but also points to potential outbreaks from bat-borne viruses or the emergence of a novel “Disease X.”
The report emphasizes that the UK’s current reliance on overseas vaccine production and complex international supply chains poses significant challenges. While some vaccines are bottled domestically, many components and ingredients are sourced from Europe, North America, and other regions. This dependence could disrupt access to vaccines in the event of geopolitical tensions, trade restrictions, or logistical obstacles.
To address these vulnerabilities, the report proposes a hybrid strategy that combines strengthening the UK’s sovereign manufacturing base with building surge capacity through international partnerships. It calls for targeted investment to alleviate critical bottlenecks across the vaccine development and production pipeline. The authors stress that these measures must be implemented proactively rather than reactively during a crisis.
Van-Tam concurs with these assessments, arguing that vaccine infrastructure should be regarded as a key element of health security. He noted that while immediate issues often dominate government spending priorities, the risk of future pandemics is too significant to be relegated. “It’s a can that’s too easily kicked down the road,” he said, advocating for timely investment to ensure preparedness.
The discussion reflects a broader international conversation about the lessons learned from the COVID-19 pandemic and the need to build resilient systems capable of responding to emerging health threats. The UK’s approach to vaccine manufacturing is likely to be reassessed in light of these warnings, seeking a balance between self-reliance and cooperation within global supply networks.